One of the first public exchange-traded funds (ETF) for the cannabis industry has now added 10 more listings for investors to rely on.

On Monday (March 19) Horizons ETFs Management announced a quarterly rebalance for the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ). Thanks to this update, an additional 10 more cannabis stocks, increase the ETFs holdings to 37 as of Tuesday.

“It’s exciting to see an increase in the number of investable companies that qualify to be included in HMMJ’s portfolio,” Steve Hawkins, president and Co-CEO of Horizons ETFs said in a statement.

Hawkins added as the industry moves closer to legalization for adult-use of cannabis in Canada, he has seen the entire sector “rapidly grow in size and breadth.”


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

This growth was made even more evident for the Horizons ETFs Management as it launched an additional marijuana ETF this year. The Horizons Emerging Marijuana Growers Index ETF (AQN:HMJR) launched on the Aequitas NEO Exchange on February 14.

The most recent ETF offers investors exposure to marijuana producers that are smaller in market capitalization.

The brand new holdings available on the Horizons Marijuana Life Sciences Index ETF are:

“Our clinical approach and pipeline of products are unique and being added to this index reinforces the credibility of our approach to the financial community,” Bernard Fortier, CEO of Tetra Bio-Pharma said in a statement.

So far in 2018, the Horizons Marijuana Life Sciences Index ETF has decreased in value 8.30 percent, up until market closure on Monday, representing a loss of $1.76 per share. At market closure on Tuesday (March 20), the ETF finished the day at $19.04.

Are investors getting the proper value from investing in ETFs?

Providing commentary for the industry, Alan Brochstein, cannabis analyst with 420 Investor wrote a column in Forbes detailing why, in his opinion, investors may want to hold on cannabis-focused ETFs despite their appeal.

“While I like the concept of an investment fund targeting cannabis stocks, the ones that have been created thus far are not well constructed for the most part,” Brochstein wrote.

Brochstein said his initial reservations with Horizons Marijuana Life Sciences Index ETF related to the inclusion of some biotech stocks, which he opined have had a negative impact on the performance of the index.

He added this ETF is a bet on Canadian licensed producers (LPs), which represent 74 percent of the fund. Brochstein conceded why investors see interest in this particular ETF:

While I continue to believe that most investors can likely do better than HMMJ by picking a few large Canadian LPs, thus avoiding the 0.75 [percent] management fee as well as exposure to a few names that don’t really make sense, I can see the appeal to those investing smaller amounts of money but who want diversification.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Editor’s Note: This story was updated to reflect the market closure data for the Horizons Marijuana Life Sciences Index ETF.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Beleave, HIKU Brands, and Isodiol International are clients of the Investing News Network. This article is not paid-for content.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) subsidiary Lyfted Farms has much to commemorate this 420 (April 20th) known as the international day of celebration and celebratory consumption of cannabis.

The Company fulfilled an impressive $100k initial order of 25 pounds of premium indoor exotic cannabis flower and concentrates that hit the shelves of 14 famed STIIIZY retail locations throughout California last week, just ahead of the biggest day in cannabis counterculture.

Keep reading... Show less